期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 11, 期 2, 页码 161-169出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2013.0024
关键词
-
类别
资金
- Infinity Pharmaceuticals
- Bristol-Myers Squibb Company
- Novartis AG
- Chugai Pharmaceutical Co., Ltd
- Pfizer Inc.
- Merck Co., Inc.
- GlaxoSmithKline plc.
EGFR mutations identify patients who are more likely to respond to treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) than cytotoxic chemotherapy. The distinct success of the first-generation EGFR TKIs erlotinib and gefitinib has been accompanied by the observation that acquired resistance to these treatments develops after a median of 1 year of treatment. Newer, second-generation EGFR TKIs have been developed with the intent to delay or overcome acquired resistance by the broader inhibition of kinases (eg, HER2 and vascular endothelial growth factor receptor) and/or altering the interactions with EGFR through irreversibly binding to the kinase domain. This article discusses many of these agents (including afatinib, dacomitinib, XL647, AP26113, and CO-1686) which have the potential for greater efficacy compared with first-generation EGFR TKIs, and may also have clinical activity against other oncogenic mutations within the EGFR family, including HER2. (JNCCN 2013;11:161-169)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据